These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29387480)

  • 1. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
    Martinelli E; Troiani T; Sforza V; Martini G; Cardone C; Vitiello PP; Ciardiello D; Rachiglio AM; Normanno N; Sartore-Bianchi A; Marsoni S; Bardelli A; Siena S; Ciardiello F
    ESMO Open; 2018; 3(1):e000299. PubMed ID: 29387480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
    Sartore-Bianchi A; Lonardi S; Martino C; Fenocchio E; Tosi F; Ghezzi S; Leone F; Bergamo F; Zagonel V; Ciardiello F; Ardizzoni A; Amatu A; Bencardino K; Valtorta E; Grassi E; Torri V; Bonoldi E; Sapino A; Vanzulli A; Regge D; Cappello G; Bardelli A; Trusolino L; Marsoni S; Siena S
    ESMO Open; 2020 Sep; 5(5):e000911. PubMed ID: 32988996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    Parikh A; Atreya C; Korn WM; Venook AP
    J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
    Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
    Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
    Sandhu J; Wang C; Fakih M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
    Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
    Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
    Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
    Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
    Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeting HER2 in colorectal cancer].
    Spitzer E; Cervera P; André T; Cohen R
    Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study.
    Fraga T; de Sousa MJ; Magalhães J; Basto R; Paulo J; Bonito N; Magalhães JP; Figueiredo P; Sousa GM
    Cureus; 2023 Jul; 15(7):e42536. PubMed ID: 37637599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer.
    Yoshikawa A; Nakamura Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
    Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
    Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
    Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
    Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
    Nakamura Y; Okamoto W; Kato T; Esaki T; Kato K; Komatsu Y; Yuki S; Masuishi T; Nishina T; Ebi H; Sawada K; Taniguchi H; Fuse N; Nomura S; Fukui M; Matsuda S; Sakamoto Y; Uchigata H; Kitajima K; Kuramoto N; Asakawa T; Olsen S; Odegaard JI; Sato A; Fujii S; Ohtsu A; Yoshino T
    Nat Med; 2021 Nov; 27(11):1899-1903. PubMed ID: 34764486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.